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Evaluation of speciﬁc immune response in early P. aeruginosa
infection in cystic ﬁbrosis patientsDear Editor,
We read with interest the recently published article by
Anstead et al. regarding Pseudomonas aeruginosa serology
and risk for re-isolation in the EPIC trial [1]. We would like
to report our experience regarding P. aeruginosa serology
during a recently conducted clinical trial on early eradica-
tion treatment against P. aeruginosa which showed a
similar efficacy between a single 28-day treatment cycle
with oral ciprofloxacin and inhaled tobramycin and oral
ciprofloxacin and inhaled colistin [2]. Our purpose was to
evaluate the anti-P. aeruginosa immune response in early
stages of P. aeruginosa infection in patients undergoing
lung eradication treatment and 6 months after treatment. For
serology the ELISA kit (Mediagnost, Reutlingen, Germany)
test for antibodies against the P. aeruginosa antigens
alkaline protease (AP), elastase (Ela), and exotoxin A
(ExoA) was used [1,3]. Positive and negative antibody titers
were evaluated according to the manufacturer's instructions.
Sera from patients presenting first ever P. aeruginosa
colonization were evaluated. Sera were collected at first
P. aeruginosa isolation (T = 0) in 43 patients and 6 months
following eradication treatment (T = 6) in 60 patients. Age
(mean ± SD) of patients at recruitment in the study was 6.5 ±
5.4 years. The treatment was considered effective in eradicating
the pathogen when 3 successive cultures were negative during
a six-month follow-up which all patients completed [4].
At the time of first P. aeruginosa isolation, the anti-P.
aeruginosa antibody titer was above the cut-off value in 6 (14%)
of 43 patients for AP, in 4 (10%) for Ela and in 10 (23%) for ExoA.Table 1
Antibody titers (mean ± SD) against P. aeruginosa antigens alkaline protease
(AP), elastase (Ela) and exotoxin A (ExoA) at T = 0 and T = 6 in patients in
whom eradication was successful and in treatment failures.
Mean at T = 0
(±SD)
Mean at T = 6
(±SD)
p value
AP (eradication) 363 (±508) 302 (±470) p = 0.05
AP (treatment failure) 447 (±611) 682 (±999)
Ela (eradication) 252 (±377) 134 (±203) p = 0.02
Ela (treatment failure) 563 (±973) 882 (±1920)
ExoA (eradication) 757 (±913) 481 (±675) p = 0.02
ExoA (treatment failure) 697 (±991) 1139 (±1347)
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.08.003At T = 0 we found no difference in the mean antibody
titers between the group of patients in which P. aeruginosa
would be eradicated and the group in which treatment would
be unsuccessful.
At T = 6 we observed a reduction of the antibody titer in
patients in whom P. aeruginosa had been cleared and increased
titers in those still harboring P. aeruginosa. Themean T = 6 titers
in relation to microbiological outcome are illustrated in the
following graph (Table 1). Ela and Exo A showed a statistically
significant difference (p b 0.05) in the two groups of patients
with a different microbiological outcome following early
eradication treatment.
In conclusion, this study confirms that the evaluation of
specific anti-P. aeruginosa antibodies may be a useful way to
monitor early P. aeruginosa infection in cystic fibrosis
patients. The antibody titers at the beginning of treatment
did not influence treatment outcomes. After early eradication
treatment, an increase in antibody titers at T = 6 is associated
with successive isolation of the pathogen and should be
carefully evaluated as a possible alarm for treatment failure.
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